J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan

Introduction: On the basis of the IMpower133 trial, atezolizumab plus carboplatin and etoposide (CE) is approved as first-line treatment for extensive-stage (ES)-SCLC. The J-TAIL-2 study evaluated atezolizumab plus CE in routine clinical practice settings. Methods: J-TAIL-2 was a prospective, multic...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Eisaku Miyauchi, MD, PhD, Makoto Nishio, MD, PhD, Kadoaki Ohashi, MD, PhD, Atsushi Osoegawa, MD, PhD, Eiki Kikuchi, MD, PhD, Hideharu Kimura, MD, PhD, Yasushi Goto, MD, PhD, Junichi Shimizu, MD, PhD, Hiroshige Yoshioka, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Nobuyuki Katakami, MD, PhD, Masahide Oki, MD, PhD, Takashi Kijima, MD, PhD, Kenichi Chikamori, MD, PhD, Kazumi Nishino, MD, PhD, Yuki Kobayashi, MS, Asako Miwa, BA, Misa Tanaka, MS, Akihiko Gemma, PhD
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-03-01
coleção:	JTO Clinical and Research Reports
Assuntos:	Extensive-stage small cell lung cancer Atezolizumab Immune checkpoint inhibitor Observational study
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S266636432400153X
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!